• English
    • العربية
  • العربية
  • Login
  • QU
  • QU Library
  •  Home
  • Communities & Collections
  • Copyrights
View Item 
  •   Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Medicine
  • Medicine Research
  • View Item
  • Qatar University Digital Hub
  • Qatar University Institutional Repository
  • Academic
  • Faculty Contributions
  • College of Medicine
  • Medicine Research
  • View Item
  •      
  •  
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Pharmacotherapeutic perspectives on nutraceuticals in the treatment of MASLD and MASH

    Icon
    View/Open
    eid-et-al-2025-pharmacotherapeutic-perspectives-on-nutraceuticals-in-the-treatment-of-masld-and-mash.pdf (142.4Kb)
    Date
    2025-05-24
    Author
    Eid, Ali H.
    Khachab, Maha
    Kobeissy, Firas
    Sahebkar, Amirhossein
    Metadata
    Show full item record
    Abstract
    Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunctionassociated steatohepatitis (MASH) continue to be serious global health concerns despite various concerted efforts. There has been significant progress in pharmacological treatments for these conditions. The recent FDA approval of resmetirom marks a milestone as the first medication specifically approved for MASH treatment.1 Nonetheless, there is an unmet need for more efficacious or adjunctive approaches. Thus, exploration of various therapeutic approaches is ever increasingly needed. One avenue that has garnered attention in the fight against MASLD and MASH is the utilization of nutraceuticals. These are food-derived products that exhibit a plethora of health benefits beyond basic nutrition. They exert several beneficial effects in the battle against cardiovascular disease, cancer, inflammation, and metabolic disease, among others, especially since most of them are plant-derived or nature-inspired.2–5 However, the current evidentiary basis for their efficacy remains limited and inconsistent. This necessitates a critical appraisal of the available literature before recommendations can be made. Recently, a consensus on the importance of diet and nutrition as integral elements of MASLD management has been published.6 This report highlights the importance of a balanced healthy diet and body weight control, as well as the integration of personalized nutritional interventions (e.g. caloric restriction and intermittent fasting).6 In addition, eating whole rather than refined grains and reducing fat/meat intake are strongly recommended. Interestingly, and in line with the premise of our perspective regarding nutraceuticals, eating healthy sources of protein, notably from plant sources, was one of the key recommendations.6 Some of the molecules that received the most attention are omega-3 fatty acids, vitamin E, curcumin, in addition to probiotics and synbiotics.
    URI
    https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105005969609&origin=inward
    DOI/handle
    http://dx.doi.org/10.1177/20406223251339388
    http://hdl.handle.net/10576/67877
    Collections
    • Medicine Research [‎1899‎ items ]

    entitlement


    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us
    Contact Us | QU

     

     

    Home

    Submit your QU affiliated work

    Browse

    All of Digital Hub
      Communities & Collections Publication Date Author Title Subject Type Language Publisher
    This Collection
      Publication Date Author Title Subject Type Language Publisher

    My Account

    Login

    Statistics

    View Usage Statistics

    Qatar University Digital Hub is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us
    Contact Us | QU

     

     

    Video